TWI765002B - 受體拮抗劑之皮下投藥 - Google Patents

受體拮抗劑之皮下投藥 Download PDF

Info

Publication number
TWI765002B
TWI765002B TW107108546A TW107108546A TWI765002B TW I765002 B TWI765002 B TW I765002B TW 107108546 A TW107108546 A TW 107108546A TW 107108546 A TW107108546 A TW 107108546A TW I765002 B TWI765002 B TW I765002B
Authority
TW
Taiwan
Prior art keywords
administered
receptor antagonist
patient
administration
pharmaceutically acceptable
Prior art date
Application number
TW107108546A
Other languages
English (en)
Chinese (zh)
Other versions
TW201840323A (zh
Inventor
馬丁 保門
馬克思 坎伯
馬克思 瑞
馬克思 萊德爾
賽巴斯汀 羅克斯
Original Assignee
瑞士商愛杜西亞製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商愛杜西亞製藥有限公司 filed Critical 瑞士商愛杜西亞製藥有限公司
Publication of TW201840323A publication Critical patent/TW201840323A/zh
Application granted granted Critical
Publication of TWI765002B publication Critical patent/TWI765002B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107108546A 2017-03-15 2018-03-14 受體拮抗劑之皮下投藥 TWI765002B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
??PCT/EP2017/056175 2017-03-15
EP2017056175 2017-03-15
WOPCT/EP2017/056175 2017-03-15

Publications (2)

Publication Number Publication Date
TW201840323A TW201840323A (zh) 2018-11-16
TWI765002B true TWI765002B (zh) 2022-05-21

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107108546A TWI765002B (zh) 2017-03-15 2018-03-14 受體拮抗劑之皮下投藥

Country Status (18)

Country Link
US (1) US11179390B2 (https=)
EP (1) EP3595666A1 (https=)
JP (3) JP7580918B2 (https=)
KR (1) KR102510832B1 (https=)
CN (1) CN110381947A (https=)
AU (1) AU2018234056B2 (https=)
BR (1) BR112019014567A2 (https=)
CL (1) CL2019002318A1 (https=)
EA (1) EA201992123A1 (https=)
IL (1) IL269286B2 (https=)
MA (1) MA49887A (https=)
MX (1) MX393334B (https=)
MY (1) MY205605A (https=)
PH (1) PH12019502111A1 (https=)
SG (1) SG11201908128YA (https=)
TW (1) TWI765002B (https=)
UA (1) UA125531C2 (https=)
WO (1) WO2018167139A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12
SMT202600015T1 (it) 2020-07-15 2026-03-09 Viatris Asia Pacific Pte Ltd Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
ATE481103T1 (de) 2003-04-09 2010-10-15 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
AU2003249865A1 (en) * 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CA2686203A1 (en) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2011160768A1 (en) 2010-06-23 2011-12-29 Stefan Kralev Medical device for self-administration of patients with acute coronary events
EP3515924B1 (en) 2016-09-22 2021-12-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (fr) * 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd Administration sous-cutanée d'un antagoniste du récepteur p2y12

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 EVA CAROFF et al.;"4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester(ACT-246475) and Its Prodrug (ACT-281959),a Novel P2Y 12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel";JOURNAL OF MEDICINAL CHEMISTRY, vol.58, no.23, 2015-12-10, pages 9133-9153 .; *
期刊 PEER TFELT-HANSEN;Parenteral vs. oral sumatriptan and naratriptan:plasma levels and efficacy in migraine.A comment,THE JOURNAL OF HEADACHE AND PAIN, vol.8, no.5, 2007-10-23, pages 273-276 . *

Also Published As

Publication number Publication date
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
SG11201908128YA (en) 2019-10-30
EP3595666A1 (en) 2020-01-22
EA201992123A1 (ru) 2020-02-25
IL269286B1 (en) 2023-04-01
JP2020510043A (ja) 2020-04-02
BR112019014567A2 (pt) 2020-02-18
US11179390B2 (en) 2021-11-23
PH12019502111A1 (en) 2020-03-16
CN110381947A (zh) 2019-10-25
WO2018167139A1 (en) 2018-09-20
IL269286B2 (en) 2023-08-01
KR102510832B1 (ko) 2023-03-15
US20200129510A1 (en) 2020-04-30
IL269286A (en) 2019-11-28
MA49887A (fr) 2020-06-24
KR20190124297A (ko) 2019-11-04
CL2019002318A1 (es) 2020-01-10
UA125531C2 (uk) 2022-04-13
JP2023052576A (ja) 2023-04-11
AU2018234056B2 (en) 2023-05-25
MY205605A (en) 2024-10-29
MX393334B (es) 2025-03-24
JP7580918B2 (ja) 2024-11-12
JP2025060907A (ja) 2025-04-10
CA3050831A1 (en) 2018-09-20
NZ757938A (en) 2024-07-05
MX2019009559A (es) 2019-10-15

Similar Documents

Publication Publication Date Title
TWI765002B (zh) 受體拮抗劑之皮下投藥
US9439952B2 (en) Rapid-acting insulin compositions
JP6896015B2 (ja) 注射速度が増大したアリピプラゾール調合物
CA3141872A1 (en) Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
EP4592294A1 (en) Novel carbamate compound and use thereof
CA3011609A1 (en) A lyophilised pharmaceutical formulation and its use
CA3050831C (en) Subcutaneous administration of a p2y12 receptor antagonist
RU2563211C2 (ru) Фармацевтическая композиция в инъекционной форме с анальгетической активностью (варианты)
TW202146022A (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
US20250312269A1 (en) Administration of a psychedelic compound by intramuscular injection
KR102934168B1 (ko) P2y12 수용체 안타고니스트를 포함하는 수성 약제학적 조성물
JP2023082167A (ja) 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора
US20230364007A1 (en) Administration of a psychedelic compound
US20220370650A1 (en) Formulations and kits for the diagnostic evaluation of infectious diseases and methods thereof
AU2024221025A1 (en) Stable protein compositions of anti-pd1 antibody
JP2025535459A (ja) エピネフリンの新規な製剤及びその使用
HK40081665A (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents